Colchicine, a drug most familiar to cardiologists for treating acute pericarditis, is steadily gaining recognition for its potential role in treating ischaemic heart disease. The recent United States Food and Drug Administration (US FDA) approval of low dose colchicine for the secondary prevention of cardiovascular events in those with established atherosclerotic disease marks a new era in preventative cardiology as the first licensed therapy to target inflammation(1). Whilst the concept of inflammation driving atherosclerosis is not novel, treatments directed at suppressing inflammation have yielded inconsistent results, with translation to clinical practice further hindered by signals of harm from serious infections. Herein we discuss the evidence behind colchicine and the upcoming landscape of inflammation-targeted therapies in cardiovascular disease.
